BillionToOne vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
IPO Nov 2025 (BLLN, Nasdaq); $273M raised; 508K+ tests in 2025; $293–299M revenue guidance FY2025.
About
BillionToOne is a leading molecular diagnostics company that has commercialized a proprietary technology platform—Quantitative Counting Templates (QCTs)—enabling detection and quantification of disease-related DNA at single base-pair resolution. This breakthrough in cell-free DNA (cfDNA) analysis underpins its two primary product lines: UNITY Screen for comprehensive prenatal genetic screening (covering carrier status, chromosomal conditions, and fetal risk) and Northstar Select for oncology therapy guidance and liquid biopsy.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.